Trial Outcomes & Findings for Examination of Myopia Progression and Soft Bifocal Contact Lens Myopia Control (NCT NCT04080128)
NCT ID: NCT04080128
Last Updated: 2026-05-06
Results Overview
test the hypothesis that less ipRGC activity (cells in the back of the eye as measured by blue light-driven inputs to the pupil response - measured by the blue decay coefficient) as measured at the Baseline BLINK 2 is associated with greater axial elongation (eye growth) over three years The hypothesis relates to the two years of multifocal contact lens wear and one year of single vision contact lens wear. As such, it uses the entire sample which experiences the same contact lens wear in the BLINK2 Study.
COMPLETED
248 participants
Three years
2026-05-06
Participant Flow
Unit of analysis: Eyes
Participant milestones
| Measure |
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
BLINK RCT Assignment: Single Vision/Baseline to Year 2:+2.50 D Multifocal/Year 2 to 3: Single Vision
Participants assigned to single vision contact lens (SCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
|---|---|---|---|
|
Overall Study
STARTED
|
78 156
|
84 168
|
86 172
|
|
Overall Study
1 year
|
76 152
|
79 158
|
86 172
|
|
Overall Study
2 years
|
74 148
|
81 162
|
86 172
|
|
Overall Study
3 years
|
72 144
|
77 154
|
86 172
|
|
Overall Study
COMPLETED
|
72 144
|
77 154
|
86 172
|
|
Overall Study
NOT COMPLETED
|
6 12
|
7 14
|
0 0
|
Reasons for withdrawal
| Measure |
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
BLINK RCT Assignment: Single Vision/Baseline to Year 2:+2.50 D Multifocal/Year 2 to 3: Single Vision
Participants assigned to single vision contact lens (SCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
|---|---|---|---|
|
Overall Study
Lost to Follow-up
|
3
|
4
|
0
|
|
Overall Study
Withdrawal by Subject
|
3
|
3
|
0
|
Baseline Characteristics
Examination of Myopia Progression and Soft Bifocal Contact Lens Myopia Control
Baseline characteristics by cohort
| Measure |
BLINK RCT Assignment (NCT02255474): +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: SVLs
n=78 Participants
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
BLINK RCT Assignment (NCT02255474): +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: SVLs
n=84 Participants
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
BLINK RCT (NCT02255474): SVLs/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=86 Participants
Participants assigned to Single Vision CL group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
Total
n=248 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
14.9 years
n=54 Participants
|
14.9 years
n=60 Participants
|
15.1 years
n=114 Participants
|
15 years
n=480 Participants
|
|
Sex: Female, Male
Female
|
51 Participants
n=54 Participants
|
40 Participants
n=60 Participants
|
55 Participants
n=114 Participants
|
146 Participants
n=480 Participants
|
|
Sex: Female, Male
Male
|
27 Participants
n=54 Participants
|
44 Participants
n=60 Participants
|
31 Participants
n=114 Participants
|
102 Participants
n=480 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
23 Participants
n=54 Participants
|
21 Participants
n=60 Participants
|
22 Participants
n=114 Participants
|
66 Participants
n=480 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
54 Participants
n=54 Participants
|
62 Participants
n=60 Participants
|
63 Participants
n=114 Participants
|
179 Participants
n=480 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=54 Participants
|
1 Participants
n=60 Participants
|
1 Participants
n=114 Participants
|
3 Participants
n=480 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
3 Participants
n=54 Participants
|
1 Participants
n=60 Participants
|
1 Participants
n=114 Participants
|
5 Participants
n=480 Participants
|
|
Race (NIH/OMB)
Asian
|
7 Participants
n=54 Participants
|
7 Participants
n=60 Participants
|
8 Participants
n=114 Participants
|
22 Participants
n=480 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
1 Participants
n=54 Participants
|
0 Participants
n=60 Participants
|
0 Participants
n=114 Participants
|
1 Participants
n=480 Participants
|
|
Race (NIH/OMB)
Black or African American
|
4 Participants
n=54 Participants
|
4 Participants
n=60 Participants
|
13 Participants
n=114 Participants
|
21 Participants
n=480 Participants
|
|
Race (NIH/OMB)
White
|
53 Participants
n=54 Participants
|
64 Participants
n=60 Participants
|
53 Participants
n=114 Participants
|
170 Participants
n=480 Participants
|
|
Race (NIH/OMB)
More than one race
|
9 Participants
n=54 Participants
|
7 Participants
n=60 Participants
|
10 Participants
n=114 Participants
|
26 Participants
n=480 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=54 Participants
|
1 Participants
n=60 Participants
|
1 Participants
n=114 Participants
|
3 Participants
n=480 Participants
|
|
Region of Enrollment
United States
|
78 participants
n=54 Participants
|
84 participants
n=60 Participants
|
86 participants
n=114 Participants
|
248 participants
n=480 Participants
|
|
Spherical equivalent (SEQ)
|
-2.97 Diopters
STANDARD_DEVIATION 1.19 • n=54 Participants
|
-3.64 Diopters
STANDARD_DEVIATION 1.64 • n=60 Participants
|
-3.70 Diopters
STANDARD_DEVIATION 1.21 • n=114 Participants
|
-3.45 Diopters
STANDARD_DEVIATION 1.40 • n=480 Participants
|
|
Axial length (AL)
|
24.86 mm
STANDARD_DEVIATION 0.81 • n=54 Participants
|
25.35 mm
STANDARD_DEVIATION 1.07 • n=60 Participants
|
25.23 mm
STANDARD_DEVIATION 0.89 • n=114 Participants
|
25.16 mm
STANDARD_DEVIATION 0.95 • n=480 Participants
|
PRIMARY outcome
Timeframe: Three yearsPopulation: Axial length average over right and left eye
test the hypothesis that thinner subfoveal choroidal thickness (a layer of blood vessels) is associated with the outcome of greater axial elongation (eye growth) The hypothesis relates to the two years of multifocal contact lens wear and one year of single vision contact lens wear. As such, it uses the entire sample which experiences the same contact lens wear in the BLINK2 Study.
Outcome measures
| Measure |
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=234 Participants
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
|
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
|---|---|---|---|
|
The Statistical Correlation Between Three-year Change in Choroidal Thickness and Three-year Change in Axial Length
|
—
|
0.18 mm axial length
Standard Deviation 0.19
|
—
|
PRIMARY outcome
Timeframe: Three yearsPopulation: Axial length average over right and left eye
test the hypothesis that less ipRGC activity (cells in the back of the eye as measured by blue light-driven inputs to the pupil response - measured by the blue decay coefficient) as measured at the Baseline BLINK 2 is associated with greater axial elongation (eye growth) over three years The hypothesis relates to the two years of multifocal contact lens wear and one year of single vision contact lens wear. As such, it uses the entire sample which experiences the same contact lens wear in the BLINK2 Study.
Outcome measures
| Measure |
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=230 Participants
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
|
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
|---|---|---|---|
|
The Statistical Correlation Between iPRGC Activity at BLINK2 Baseline and Three-year Change in Axial Length
|
—
|
0.18 mm axial length
Standard Deviation 0.18
|
—
|
PRIMARY outcome
Timeframe: Three yearsPopulation: Axial length measured as the average of the right and left eye.
test the hypothesis that exposure to light levels over 1000 lux as measured at the Baseline BLINK2 visit is associated with less axial elongation (eye growth) over three years The hypothesis relates to the two years of multifocal contact lens wear and one year of single vision contact lens wear. As such, it uses the entire sample which experiences the same contact lens wear in the BLINK2 Study.
Outcome measures
| Measure |
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=230 Participants
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
|
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
|---|---|---|---|
|
The Statistical Correlation Between Light Levels Measured at Baseline and Three-year Change in Axial Length
|
—
|
0.18 mm axial length
Standard Deviation 0.18
|
—
|
PRIMARY outcome
Timeframe: 3 yearsPopulation: Right eye only
The three-year change from baseline to three years for choroidal thickness.
Outcome measures
| Measure |
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=234 Participants
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
|
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
|---|---|---|---|
|
Three-year Choroidal Thickness Change
|
—
|
6.12 microns
Standard Deviation 33.73
|
—
|
PRIMARY outcome
Timeframe: BaselinePopulation: exposure received by both eyes
Baseline light exposure as measured by minutes at light levels over 1000 lux. Light exposure was monitored using the Actiwatch2 (Phillips Respironics), a light-sensing and logging watch worn on the wrist. Participants wore the device for a 1 week period to monitor environmental light exposure. The illuminance was measured in lux every minute. Data were scrubbed of periods where the watch was not worn or other artifacts. Light levels over 1000 lux were added to determine time outdoors in minutes.
Outcome measures
| Measure |
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=230 Participants
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
|
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
|---|---|---|---|
|
Duration of Exposure to Light Levels Exceeding 1000 Lux at Baseline
|
—
|
51.28 minutes of light exposure over 1000 lux
Standard Deviation 51.87
|
—
|
PRIMARY outcome
Timeframe: BaselinePopulation: Right eyes
Baseline iPRGC activity (cells in the back of the eye as measured by blue light-driven inputs to the pupil response - measured by the blue decay coefficient). The Blue Decay Coefficient represents the rate at which the pupil redilates in the dark after exposure to multiple 5-second pulses of red and blue light. The redilation data are fit by an exponential decay function eβt where t is time in seconds and the coefficient β is the natural log of the percent change in pupil diameter per second. Values range from -0.30 to -0.01. More positive values represent slower pupil redilation and are associated with greater, potentially beneficial ipRGC activity.
Outcome measures
| Measure |
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=230 Participants
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
|
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
|---|---|---|---|
|
Baseline iPRGC Activity
|
—
|
-0.13 unitless
Standard Deviation 0.06
|
—
|
SECONDARY outcome
Timeframe: BaselinePopulation: Right eyes of participants. Using method of Anderson and Stuebing. Anderson HA, Stuebing KK. Subjective versus Objective Accommodative Amplitude: Preschool to Presbyopia. Optom Vis Sci 2014;91:1290-301.
Testing the hypothesis that long-term soft bifocal contact lens wear does not alter accommodative amplitude. This hypothesis predicts that at the baseline BLINK2 Study visit, the accommodative amplitude will be similar across the three treatment groups that were randomly assigned at the beginning of the BLINK Study (NCT02255474). Assessed data from the beginning of the BLINK Study up to the BLINK2 Study Baseline Visit approximately 4.7 years, BLINK2 Study Baseline Visit reported
Outcome measures
| Measure |
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=86 Eyes
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=78 Eyes
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
|
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=84 Eyes
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
|---|---|---|---|
|
Accommodative Amplitude
|
5.76 Diopters
Interval 5.4 to 6.12
|
5.72 Diopters
Interval 5.34 to 6.11
|
5.41 Diopters
Interval 5.05 to 5.78
|
SECONDARY outcome
Timeframe: BaselinePopulation: Right eyes analyzed. near point rod with a card containing 2.06 M (20/125 Snellen equivalent) was placed at 33 cm (a 3D accommodative stimulus) in front of the right eye while the contralateral eye was occluded. The participant was encouraged to keep the letters clear until at least five valid readings were obtained. The average spherical equivalent was added to 3 (the accommodative stimulus), so accommodative lag is positive and accommodative lead is negative.
Testing the hypothesis that long-term soft bifocal contact lens wear does not alter accommodative lag. This hypothesis predicts that at the baseline BLINK2 Study visit, the accommodative lag will be similar across the three treatment groups that were randomly assigned at the beginning of the BLINK Study (NCT02255474). Assessed data from the beginning of the BLINK Study up to the BLINK2 Study Baseline Visit approximately 4.7 years, BLINK2 Study Baseline Visit reported.
Outcome measures
| Measure |
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=86 Eyes
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=78 Eyes
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
|
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=84 Eyes
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
|---|---|---|---|
|
Lag of Accommodation
|
1.63 Diopters
Interval 1.5 to 1.75
|
1.69 Diopters
Interval 1.53 to 1.83
|
1.77 Diopters
Interval 1.65 to 1.9
|
SECONDARY outcome
Timeframe: BaselinePopulation: The participant focused on a 20/32 letter on the card, and +2.00-D lenses and -2.00 D lenses using flippers. The accommodative facility was recorded as the number of times the participant cleared the letters (flips), divided by two to yield cycles per minute to the nearest 0.5 cycles.
Testing the hypothesis that long-term soft bifocal contact lens wear does not alter accommodative facility. This hypothesis predicts that at the baseline BLINK2 Study visit, the accommodative lag will be similar across the three treatment groups that were randomly assigned at the beginning of the BLINK Study (NCT02255474). Assessed data from the beginning of the BLINK Study up to the BLINK2 Study Baseline Visit approximately 4.7 years, BLINK2 Study Baseline Visit reported.
Outcome measures
| Measure |
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=86 Participants
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=78 Participants
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
|
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=84 Participants
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
|---|---|---|---|
|
Accommodative Facility
|
9.51 cycles/min
Interval 8.72 to 10.3
|
9.46 cycles/min
Interval 8.63 to 10.29
|
9.17 cycles/min
Interval 8.38 to 9.97
|
SECONDARY outcome
Timeframe: Two year change (Baseline to 2-Year visit)Population: Right and left eyes averaged
Test the hypothesis that wearing +2.50 D multifocal contact lenses slow rather than merely delay myopia progression. This null hypothesis predicts that during the first two years of the BLINK2 Study, when all subjects will wear +2.50 D multifocal contact lenses, axial length elongation at the same rate regardless of original lens assignment (i.e., +2.50 D multifocal lenses, +1.50 D multifocal lenses, SVLs). Alternatively, faster myopia progression in subjects originally fitted with soft bifocal contact lenses compared to single vision contact lenses would indicate a delay in myopia progression rather than a permanent treatment benefit. Measured as the change the baseline BLINK2 visit to the 2 year visit on the IOLMaster which is not the entire time frame of the study - as detailed in the specific aims from the funded grant proposal. Because the exposures before the baseline visit were part of NCT02255474 immediately before this cohort, the original groups were analyzed.
Outcome measures
| Measure |
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=86 Eyes
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=78 Eyes
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
|
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=84 Eyes
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
|---|---|---|---|
|
Slowing of Myopia Progression - Axial Length
|
25.28 mm
Interval 25.07 to 25.5
|
24.95 mm
Interval 24.71 to 25.18
|
25.33 mm
Interval 25.09 to 25.57
|
SECONDARY outcome
Timeframe: One year change (2-year visit to 3-year visit)Population: Right and left eye averaged
The investigators will test the hypothesis that there is no increase in myopia when switching from +2.50 D multifocal contact lenses to single vision contact lenses in Year 2 of the BLINK2 observational study. This hypothesis predicts that the progression of myopia during the last year of follow-up when all subjects will switch to single vision contact lenses, will be similar to myopia progression during the first two years when all subjects wore multifocal contact lenses. Alternatively, faster progression after switching to single vision contact lens wear indicates a "rebound" of myopia progression. This aim was specifically designed to measure what happened between the 2nd and 3rd annual visit which is not the entire time frame of the study - as detailed in the specific aims from the funded grant proposal. Because the entire cohort was wearing the same contact lens, it uses all participants together.
Outcome measures
| Measure |
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=248 Eyes
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
|
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
|---|---|---|---|
|
Rebound of Progression - Axial Length
|
—
|
0.03 mm
Interval 0.01 to 0.05
|
—
|
SECONDARY outcome
Timeframe: One year change (2-year visit to 3-year visit)Population: Right and left eye averaged
The investigators will test the hypothesis that there is no increase in myopia, as measured by the change in the spherical equivalent, when switching from +2.50 D multifocal contact lenses to single vision contact lenses in Year 2 of the BLINK2 observational study. This hypothesis predicts that the progression of myopia during the last year of follow-up when all subjects will switch to single vision contact lenses, will be similar to myopia progression during the first two years when all subjects wore multifocal contact lenses. Alternatively, faster progression after switching to single vision contact lens wear indicates a "rebound" of myopia progression. This aim was specifically designed to measure what happened between the 2nd and 3rd annual visit which is not the entire time frame of the study - as detailed in the specific aims from the funded grant proposal. Because the entire cohort was wearing the same contact lens, it uses all participants together.
Outcome measures
| Measure |
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=248 Eyes
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
|
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
|---|---|---|---|
|
Rebound of Progression - Myopia Progression
|
—
|
-0.17 Diopters
Interval -0.22 to -0.12
|
—
|
SECONDARY outcome
Timeframe: Two year change (Baseline visit to 2-year visit)Population: Right and left eyes averaged
Test the hypothesis that wearing +2.50 D multifocal contact lenses slow rather than merely delay myopia progression. This null hypothesis predicts that during the first two years of the BLINK2 Study, when all subjects will wear +2.50 D multifocal contact lenses, participants will have myopia progression, as measured by spherical equivalent, at the same rate regardless of original lens assignment (i.e., +2.50 D multifocal lenses, +1.50 D multifocal lenses, SVLs). Alternatively, faster myopia progression in those with soft bifocal contact lenses compared to SVLs would indicate a delay in myopia progression rather than a permanent treatment benefit. Measured between Baseline and Year 2 of the BLINK2 Study which is not the entire time frame of the study - as detailed in the specific aims from the funded grant proposal. Because the exposures before the baseline visit were part of NCT02255474 immediately before this cohort, the original groups were analyzed.
Outcome measures
| Measure |
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=86 Eyes
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=78 Eyes
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
|
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=84 Eyes
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
|
|---|---|---|---|
|
Slowing of Myopia Progression - Myopia Progression
|
-3.87 Diopters
Interval -4.19 to -3.54
|
-3.15 Diopters
Interval -3.51 to -2.8
|
-3.89 Diopters
Interval -4.25 to -3.53
|
Adverse Events
+2.50 D/+2.50 D Multifocal Contact Lens
+1.50 D/+2.50 D Multifocal Contact Lens
Single Vision Contact Lenses (SVL)/+2.50 D MCL
Serious adverse events
| Measure |
+2.50 D/+2.50 D Multifocal Contact Lens
n=78 participants at risk
Participants assigned to +2.50 D multiple contact lens (MCL) group in BLINK, in +2.50 D in BLINK2
|
+1.50 D/+2.50 D Multifocal Contact Lens
n=84 participants at risk
Participants assigned to +1.50 D multiple contact lens (MCL) group in BLINK, in +2.50 D in BLINK2
|
Single Vision Contact Lenses (SVL)/+2.50 D MCL
n=86 participants at risk
Participants assigned to SVL group in BLINK, in +2.50 D in BLINK2
|
|---|---|---|---|
|
Psychiatric disorders
Mental health issue
|
1.3%
1/78 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
0.00%
0/84 • Three years
Adverse events were classified as determined by the Executive Committee.
|
1.2%
1/86 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Immune system disorders
Allergic reaction: non-ocular
|
1.3%
1/78 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
0.00%
0/84 • Three years
Adverse events were classified as determined by the Executive Committee.
|
0.00%
0/86 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Nervous system disorders
Concussion
|
1.3%
1/78 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
0.00%
0/84 • Three years
Adverse events were classified as determined by the Executive Committee.
|
0.00%
0/86 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Nervous system disorders
Headache
|
1.3%
1/78 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
0.00%
0/84 • Three years
Adverse events were classified as determined by the Executive Committee.
|
0.00%
0/86 • Three years
Adverse events were classified as determined by the Executive Committee.
|
Other adverse events
| Measure |
+2.50 D/+2.50 D Multifocal Contact Lens
n=78 participants at risk
Participants assigned to +2.50 D multiple contact lens (MCL) group in BLINK, in +2.50 D in BLINK2
|
+1.50 D/+2.50 D Multifocal Contact Lens
n=84 participants at risk
Participants assigned to +1.50 D multiple contact lens (MCL) group in BLINK, in +2.50 D in BLINK2
|
Single Vision Contact Lenses (SVL)/+2.50 D MCL
n=86 participants at risk
Participants assigned to SVL group in BLINK, in +2.50 D in BLINK2
|
|---|---|---|---|
|
Eye disorders
Allergy: ocular
|
5.1%
4/78 • Number of events 4 • Three years
Adverse events were classified as determined by the Executive Committee.
|
6.0%
5/84 • Number of events 5 • Three years
Adverse events were classified as determined by the Executive Committee.
|
8.1%
7/86 • Number of events 7 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Eye disorders
BV/accommodation issue
|
3.8%
3/78 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
|
1.2%
1/84 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
1.2%
1/86 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Immune system disorders
Allergy: non-ocular
|
1.3%
1/78 • Number of events 2 • Three years
Adverse events were classified as determined by the Executive Committee.
|
2.4%
2/84 • Number of events 2 • Three years
Adverse events were classified as determined by the Executive Committee.
|
3.5%
3/86 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Eye disorders
Contact lens acute red eye
|
0.00%
0/78 • Three years
Adverse events were classified as determined by the Executive Committee.
|
0.00%
0/84 • Three years
Adverse events were classified as determined by the Executive Committee.
|
1.2%
1/86 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
General disorders
Uncategorized
|
1.3%
1/78 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
0.00%
0/84 • Three years
Adverse events were classified as determined by the Executive Committee.
|
3.5%
3/86 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Nervous system disorders
Concussion
|
3.8%
3/78 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
|
2.4%
2/84 • Number of events 2 • Three years
Adverse events were classified as determined by the Executive Committee.
|
1.2%
1/86 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Eye disorders
Conjunctivitis
|
3.8%
3/78 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
|
3.6%
3/84 • Number of events 4 • Three years
Adverse events were classified as determined by the Executive Committee.
|
3.5%
3/86 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Eye disorders
Corneal epithelial defect/erosion
|
2.6%
2/78 • Number of events 2 • Three years
Adverse events were classified as determined by the Executive Committee.
|
1.2%
1/84 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
0.00%
0/86 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Eye disorders
Corneal scar, new
|
2.6%
2/78 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
|
9.5%
8/84 • Number of events 9 • Three years
Adverse events were classified as determined by the Executive Committee.
|
15.1%
13/86 • Number of events 18 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Eye disorders
Dry eye
|
2.6%
2/78 • Number of events 2 • Three years
Adverse events were classified as determined by the Executive Committee.
|
3.6%
3/84 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
|
1.2%
1/86 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Eye disorders
Foreign body
|
2.6%
2/78 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
|
0.00%
0/84 • Three years
Adverse events were classified as determined by the Executive Committee.
|
1.2%
1/86 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Eye disorders
Giant papillary conjunctivitis
|
5.1%
4/78 • Number of events 4 • Three years
Adverse events were classified as determined by the Executive Committee.
|
1.2%
1/84 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
2.3%
2/86 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Eye disorders
Hordeolum/chalazion
|
6.4%
5/78 • Number of events 5 • Three years
Adverse events were classified as determined by the Executive Committee.
|
4.8%
4/84 • Number of events 4 • Three years
Adverse events were classified as determined by the Executive Committee.
|
5.8%
5/86 • Number of events 5 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Eye disorders
Infiltrative keratitis
|
5.1%
4/78 • Number of events 4 • Three years
Adverse events were classified as determined by the Executive Committee.
|
3.6%
3/84 • Number of events 4 • Three years
Adverse events were classified as determined by the Executive Committee.
|
5.8%
5/86 • Number of events 5 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Psychiatric disorders
Mental health issue
|
12.8%
10/78 • Number of events 14 • Three years
Adverse events were classified as determined by the Executive Committee.
|
8.3%
7/84 • Number of events 8 • Three years
Adverse events were classified as determined by the Executive Committee.
|
12.8%
11/86 • Number of events 14 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Eye disorders
Optic nerve issue
|
2.6%
2/78 • Number of events 2 • Three years
Adverse events were classified as determined by the Executive Committee.
|
1.2%
1/84 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
0.00%
0/86 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Product Issues
Poor contact lens fit
|
0.00%
0/78 • Three years
Adverse events were classified as determined by the Executive Committee.
|
0.00%
0/84 • Three years
Adverse events were classified as determined by the Executive Committee.
|
1.2%
1/86 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Eye disorders
Possible microbial keratitis
|
0.00%
0/78 • Three years
Adverse events were classified as determined by the Executive Committee.
|
1.2%
1/84 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
0.00%
0/86 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Eye disorders
Retinal issue
|
9.0%
7/78 • Number of events 7 • Three years
Adverse events were classified as determined by the Executive Committee.
|
9.5%
8/84 • Number of events 9 • Three years
Adverse events were classified as determined by the Executive Committee.
|
12.8%
11/86 • Number of events 14 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Product Issues
Contact lens solution issue
|
3.8%
3/78 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
|
3.6%
3/84 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
|
2.3%
2/86 • Number of events 2 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Eye disorders
Sterile corneal ulcer
|
0.00%
0/78 • Three years
Adverse events were classified as determined by the Executive Committee.
|
1.2%
1/84 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
1.2%
1/86 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Eye disorders
Subconjunctival hemorrhage
|
0.00%
0/78 • Three years
Adverse events were classified as determined by the Executive Committee.
|
1.2%
1/84 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
0.00%
0/86 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
General disorders
Systemic disease
|
15.4%
12/78 • Number of events 18 • Three years
Adverse events were classified as determined by the Executive Committee.
|
17.9%
15/84 • Number of events 21 • Three years
Adverse events were classified as determined by the Executive Committee.
|
8.1%
7/86 • Number of events 8 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Eye disorders
Transient visual disturbance
|
0.00%
0/78 • Three years
Adverse events were classified as determined by the Executive Committee.
|
1.2%
1/84 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
0.00%
0/86 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
General disorders
Trauma: non-ocular
|
10.3%
8/78 • Number of events 13 • Three years
Adverse events were classified as determined by the Executive Committee.
|
10.7%
9/84 • Number of events 9 • Three years
Adverse events were classified as determined by the Executive Committee.
|
18.6%
16/86 • Number of events 18 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Eye disorders
Trauma: ocular
|
1.3%
1/78 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
2.4%
2/84 • Number of events 2 • Three years
Adverse events were classified as determined by the Executive Committee.
|
2.3%
2/86 • Number of events 2 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Product Issues
Unspecified contact lens issues
|
0.00%
0/78 • Three years
Adverse events were classified as determined by the Executive Committee.
|
0.00%
0/84 • Three years
Adverse events were classified as determined by the Executive Committee.
|
1.2%
1/86 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Eye disorders
Visual symptoms - no obvious cause
|
0.00%
0/78 • Three years
Adverse events were classified as determined by the Executive Committee.
|
0.00%
0/84 • Three years
Adverse events were classified as determined by the Executive Committee.
|
1.2%
1/86 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
|
|
Nervous system disorders
Headache
|
10.3%
8/78 • Number of events 9 • Three years
Adverse events were classified as determined by the Executive Committee.
|
11.9%
10/84 • Number of events 11 • Three years
Adverse events were classified as determined by the Executive Committee.
|
5.8%
5/86 • Number of events 6 • Three years
Adverse events were classified as determined by the Executive Committee.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place